Why the study?
Does adding aliskiren to losartan and optimal antihypertensive therapy reduce urinary aldosterone excretion in patients with type 2 diabetes and nephropathy?
Does adding aliskiren to losartan and optimal antihypertensive therapy reduce urinary aldosterone excretion in patients with type 2 diabetes and nephropathy?
Adding aliskiren to losartan significantly reduces urinary aldosterone excretion in patients with type 2 diabetes and nephropathy, which may attenuate kidney function decline.
Hypothesis-generating for aliskiren add-on in diabetic nephropathy; leaves open clinical renal benefit.
Adding aliskiren to recommended renoprotective treatment with losartan and optimal antihypertensive therapy provided significant reductions in urinary aldosterone excretion which may attenuate decline in kidney function.
No takes yet. Share an insight, caveat, or question.
Persson et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: